Johnson & Johnson

Johnson & Johnson drifted lower Friday, trading near the middle of its $151-$255 range. The stock carries a P/E of 29.14 on trailing earnings of $8.65 a share, a premium that reflects the steady margin profile more than growth. Revenue advanced 7.9% year over year, but EPS declined 3.9% over the same stretch. That divergence shows up in the Alpha Score: momentum at 99.4, value at 41.2. Quality scores a respectable 60.9, aided by the 21.8% net margin. Sentiment sits right at the midpoint. Next week brings the quarterly ex-dividend date. The payout has been a consistent floor for the stock in past years, and with the 52-week low still 42% below current levels, income buyers may provide support in a defensive rotation.

Johnson & Johnson paid $30 million upfront for Nanobiotix's tumor-injected radiation enhancer. The Phase 3 sarcoma readout arrives in the second half of 2025, a binary catalyst for the partnership. JNJ's Alpha Score sits at 60.4, with momentum scoring 80 but value at 44.7. The stock's net margin of 21.8% reflects the high-margin pharma model, but EPS fell 3.9% year over year even as revenue rose 7.9%. The company trades at 26 times earnings, above the sector median, partly justified by its quality score of 60.9. Sentiment is neutral at 50. Watch the second half of 2025: the Nanobiotix readout will either validate a new radiotherapy platform or reset expectations for the pipeline.

Johnson & Johnson shares traded flat Monday, holding near the middle of a wide 52-week range that stretches from $149 to $251. The stock sits at roughly $200, a level that has acted as both support and resistance since early March. The company's Alpha Score of 59.2 reflects a split picture. Momentum scores 76, helped by a 7.9% revenue gain last quarter. Quality sits at 60.9 with net margins above 21%. But value scores just 44.7 at 26 times earnings, and EPS fell 3.9% year over year. Sentiment is neutral at 50. Trump's Pennsylvania visit to Mack Trucks on Monday focused on manufacturing jobs and deregulation. No direct JNJ policy announcements came from the event, but the broader deregulatory tone keeps healthcare M&A and drug pricing rules in focus for the sector. Next watch: JNJ's next quarterly report, expected in mid-April, will show whether revenue growth can outpace the earnings decline.

Johnson & Johnson sits near the middle of its 52-week range after a year that split top-line momentum from bottom-line pressure. Revenue climbed 7.9% year over year, but earnings per share dropped 3.9% — a divergence that leaves the stock trading at 26 times trailing earnings. Net margin held at 21.8%, a bright spot for a company that relies on both pharmaceuticals and medical devices. The Alpha Score of 57.3 reflects strong momentum at 69.6 but weaker value at 44.7. Quality scores above 60, sentiment at exactly 50 — the market is not leaning aggressively either way. The next quarterly report will test whether JNJ can translate revenue growth into earnings recovery, especially as consensus expects a return to positive EPS growth.

Johnson & Johnson shares sit near the middle of a wide 52-week range as the company pushes toward a historic revenue milestone. Management expects JNJ to become the first pharmaceutical group to cross $100bn in annual revenue by 2026, a target that would cement its position in a portfolio heavy on AI exposure. The Alpha Score of 56.7 reflects a split profile. Momentum scores 67.7, supported by steady earnings and a 7.9% revenue gain last year. Quality holds at 60.9 with a net margin above 20%. But value comes in at 44.7 — a P/E of 26.13 offers little discount relative to peers. EPS contracted 3.9% year over year, weighing on the earnings growth story. The next catalyst is the second-quarter earnings report, due in mid-July. Investors will watch whether revenue acceleration can reverse the earnings decline and whether margins hold above 20%.